From Wikipedia, the free encyclopedia
Clinical data
Trade namesLusefi
Other namesTS-071
ATC code
Legal status
Legal status
  • Rx-only in Japan
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass434.55 g·mol−1
3D model (JSmol)
  • CCOC1=CC=C(C=C1)CC2=C(C=C(C(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](S3)CO)O)O)O)OC)C

Luseogliflozin (trade name Lusefi) is a pharmaceutical drug (an SGLT2 inhibitor) used for the treatment of type 2 diabetes mellitus.[1][2] It was approved for use in Japan in 2014.[1] In a meta-analysis involving data from 10 randomized controlled trials (1304 patients), Dutta et. al. demonstrated the good glycaemic efficacy (mean glycated hemoglobin reduction of -0.76% and mean fasting glucose reduction of -26.69mg/dl) and safety of luseogliflozin 2.5mg/day as compared to placebo. Additional benefits include significant reduction in systolic blood pressure (-4.19 mm Hg), serum triglycerides (-12.60mg/dl), uric acid (-0.48mg/dl) and alanine aminotransferase (-4.11 IU/L) as compared to placebo, highlighting the beneficial impact on the different aspects of metabolic syndrome. [3]


  1. ^ a b Markham A, Elkinson S (June 2014). "Luseogliflozin: first global approval". Drugs. 74 (8): 945–50. doi:10.1007/s40265-014-0230-8. PMID 24848756. S2CID 1770988.
  2. ^ Samukawa Y, Sata M, Furihata K, Ito T, Ueda N, Ochiai H, et al. (September 2017). "Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study". Clinical Pharmacology in Drug Development. 6 (5): 439–447. doi:10.1002/cpdd.364. PMID 28783873.
  3. ^ Dutta D, Kadian J, Mahajan K, Dhall A, Sharma M (Mar 2023). "Efficacy and safety of luseogliflozin in improving glycaemic and non-glycaemic outcomes in type-2 diabetes: A meta-analysis". Diabetes Metab Syndr. 17 (3): 102742. doi:10.1016/j.dsx.2023.102742. PMID 36933330.